Business
Peel Hunt Appointed as Joint Broker
Peel Hunt Appointed as Joint Broker.
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n\n \n \n \n \n \n \n20 September 2023\n \nAvacta Group plc\n \n(\"Avacta\" or the \"Company\" and, together with its subsidiary undertakings, the \"Group\")\n \nPeel Hunt Appointed as Joint Broker\n \n Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that it has appointed Peel Hunt LLP (\"Peel Hunt\") as Joint Broker alongside Stifel Nicolaus Europe which acts as Broker and Nomad to the Company.\n \n-Ends-\n \nFor further information from Avacta Group plc, please contact:\n \n\n\n\nAvacta Group plc\nAlastair Smith, Chief Executive Officer\nTony Gardiner, Chief Financial Officer\nMichael Vinegrad, Group Communications Director\n \n\n\nTel: +44 (0) 1904 21 7070\nwww.avacta.com\n\n\n\n\nStifel Nicolaus Europe Limited (Nomad and Broker)\nNicholas Moore / Nick Adams / Samira Essebiyea / Nick Harland / Dhiren Suares / William Palmer-Brown\n \n\n\nTel: +44 (0) 207 710 7600\nwww.stifel.com\n\n\n\n\nPeel Hunt\nJames Steel/ Chris Golden/ Patrick Birkholm\n \nICR Consilium\nMary-Jane Elliott / Jessica Hodgson / Sukaina Virji\n\n\nTel: +44 (0) 207 418 8900\nwww.peelhunt.com\n \n \[email protected]\n \n\n\n\n \nAbout Avacta Group plc - www.avacta.com\n \nAvacta Group plc is a life sciences company working to improve people's health and well-being through innovative oncology drugs and powerful diagnostics. Operating through two divisions, Diagnostics and Therapeutics, the Group's mission is to provide professionals and consumers with solutions that improve healthcare, fitness and well-being.\n \nAvacta's Therapeutics Division, a clinical stage oncology drug innovator, is building a wholly owned pipeline of novel Affimer® immunotherapies and pre|CISION™ tumour targeted chemotherapies. This approach is designed to address the lack of a durable response to current cancer immunotherapies experienced by most patients and reduce the severe systemic toxicities caused by chemotherapies. There are five programmes in the pipeline as well as several global research collaborations and licensing partnerships. Avacta's lead programme, AVA6000, is a pre|CISION™ tumour-targeted form of the established chemotherapy doxorubici...